Kopin is a name to watch from the sidelines because dilution risk outweighs its promising technology for now. Q2 revenue rose 51% to $12.7M, but core product revenue was flat at $7.6M; the gain came from $5.1M in grants and partner-funded R&D. Excluding investment gains and a tax benefit, it runs about a $3.5M operating loss, with $24.3M usable cash and $26M tied up in the BlueRadios appeal bond. Positive free cash flow is targeted for Q4 2026; any ramp snag raises the odds of a share sale. x.com

